A recent population-based analysis from Nam and coauthors found high complication rates occurring within 5 years of prostatectomy or radiation therapy interventions for prostate cancer. These findings emphasize that treatments should be reserved for men at significant risk of disease progression, and perhaps further concentrated into higher-volume centres of excellence. The optimal approach for the management of localized prostate cancer remains the subject of much controversy that focuses primarily on questions of variations across treatments in terms of oncological efficacy and toxi city. A recent paper published by Nam et al.
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A new look at prostate cancer treatment complications
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A recent population-based analysis from Nam and coauthors found high complication rates occurring within 5 years of prostatectomy or radiation therapy interventions for prostate cancer. These findings emphasize that treatments should be reserved for men at significant risk of disease progression, and perhaps further concentrated into higher-volume centres of excellence. The optimal approach for the management of localized prostate cancer remains the subject of much controversy that focuses primarily on questions of variations across treatments in terms of oncological efficacy and toxi city. A recent paper published by Nam et al. 1 This report was unique in its focus on longer term-within 5 years-treatmentrelated complications aside from urinary inconti nence and erectile dysfunction, domains that have been already exhaustively studied. The primary finding was the high rates of complications overall. Patients who under went prostatectomy required more urinary interventions, whereas patients who received radiotherapy were hospitalized more fre quently for compli cations, and required more anorectal procedures and open operations. Patients receiving radiotherapy also had more secondary malignancies.
An obvious major strength of this paper is its analysis of a populationbased database. Canada's provincial singlepayor system lends itself well to such analysis, and avoids some of the major limitations of US Medicare analyses (such as restriction to men >65 years of age and to those patients enrolled specifically in Medicare feeforservice rather than managed care). Administrative claims data are better suited for the purposes of identifying short term to intermediateterm complications than they are for determining qualityof life outcomes, for which patientreported o utcomes are by far the more valid metrics. 2 The data source of the article by Nam et al. 1 is limited, however, in its external validity. The authors do not discuss the extent to which practices and outcomes in Ontario may differ from those in other provinces. Moreover, it is wellestablished that perioperative complications of prosta tectomy vary inversely with hospital and surgeon case volume: higher volume sur geons cause fewer complications and their patients have less incontinence and require fewer procedures. 3 Information regarding these parameters of surgeon and/or hospi tal volume in the Ontario database would have been helpful. For a rough projection: the 15,870 cases of prostatectomy identified in the database over 8 years correspond to about 1,984 cases per year. Ontario's uro logical workforce has been estimated at 200 urologists;
4 the average volume of 9.9 prosta tectomy procedures per urologist thus calcu lated compares well with the 7.1 procedures observed in a US populationbased analysis. 5 Notably, the volume of radical prostatecto mies is not distributed evenly, and it is quite likely that in Ontario (as in the USA), a rela tively small number of urologists do a high volume of procedures while many do few procedures; in the US analysis, the median prostatectomy volume was only three. 5 Similar analyses of men undergoing brachytherapy found that those patients treated by higher volume practitioners have better oncological outcomes, but not necessarily lower toxicity. 6 Few data exist regarding the volume-outcomes relation ship related to externalbeam radiotherapy (EBRT). In any case, the lack of distinc tion between EBRT and brachytherapy in the Nam et al. 1 study is an acknowledged limitation, as these treatments are associ ated with somewhat d ivergent patterns of complications.
The paper analysed only open radical prostatectomy, as laparoscopic prostatec tomy, with or without robot assistance, was uncommon in Ontario during the study period (2002-2009).
1 By contrast, by the end of this period in the USA, these approaches accounted for nearly half of cases.
2 This rapid evolution in practice patterns may limit the applicability of the findings from Nam et al. 1 for US practice. Although oncological outcomes between open and robotassisted radical prostatec tomy seem to be essentially comparable, 7 the impact of the surgical approach on quality of life-s pecifically urinary and sexual function-is more controversial, and the results of analyses depend heavily on how assessments were performed, when, and among which patients. On the one hand, the preponderance of evidence on this question suggests that for these Key points ■ Prostatectomy and radiation therapy are both associated with significant risks of complications requiring hospitalization and/or surgical intervention within the first 5 years after treatment ■ Minimizing this burden of complications involves both avoiding overtreatment among men with low-risk disease, and concentrating treatment efforts in higher volume centres with demonstrable high-quality outcomes ''
An obvious major strength of this paper is its analysis of a population-based database '' PROSTATE CANCER outcomes the approach and technology are less important than the skill and experi ence of the surgeon. 8 On the other hand, there seems to be little question that robot assisted prostatectomy is associated with fewer shortterm complications than open radical prostatectomy, including at least a 50% relative reduction in peri operative mortality, and significant i mprovements in multiple other categories. 2, 7 The differences in rates of secondary malignancy are striking. However, the fact that the differences in rates are at least as great for outoffield malignancies (such as lung cancer) as for infield pelvic malignan cies suggests that this observation may be confounded by greater age, comorbidity, and adverse environmental and/or lifestyle factors among the group treated with radio therapy. On a more general note, Nam et al. 1 began with the premise that there are no survival differences following surgery or radiation. In point of fact, a growing body of literature indicates that radical prosta tectomy is associated with improved riskadjusted cancerspecific and overall mortality compared with EBRT, and that the greatest benefits are observed in men with higherrisk tumours. 9 Perhaps the most important message of the paper by Nam et al. 1 is that all prostate cancer treatments are associated with risks of compli cations, and that men should be exposed to these risks only if they are likely to obtain a survival benefit from treatment. In the setting of early detection efforts, nearly half of newly diagnosed prostate cancers are characterized as having a low risk of progression. For many of the men with these tumours, early intervention does not affect oncological outcomes, and a growing consensus supports active sur veillance rather than immediate treatment for men with these lowrisk tumours, as a strategy to defer or avoid the potential risks of radical p rostatectomy, radiotherapy, and other treatments. 10 Nam et al. 1 suggest that their population based complication rates are 'more accu rate' than the lower rates reported from centres of excellence. This is not really a fair statement; the simple truth is that highvolume provi ders achieve better out comes. This concept is an important one, as summary statements regarding prostate cancer manage ment and decision aids based on such statements routinely report only the populationbased results, ignoring a large body of evidence indicating what is achiev able in high volume settings. In truth, both cohort reports and populationbased analyses must be considered in making overall assessments of p rostate cancer treatment outcomes.
Ultimately, however, the best way to track prostate cancer treatment outcomes is not through delayed retrospective analysis of administrative claims, but rather through prospective collection of clinical and patientreported data through a disease registry, with nearreal time feedback to providers on their own performance. The American Urological Association (AUA) has recently announced the launch of exactly such a registry for the US, the AUA Quality (AQUA) registry (www.auanet. org/aqua), which is expected to yield high quality data on practice patterns and outcomes to drive the next generation of prostate cancer research. Muddying the waters by overlooking treatment modality
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Although large, population-based studies are a powerful tool for elucidating real-world outcomes and uncommon events, confounding factors must be tightly controlled. A recent report from Nam and coauthors has neglected such a confounding factor and, therefore, stands in need of further study to clarify the findings. Patients with prostate cancer often choose between various forms of radiotherapy and radical prostatectomy in situations in which cancer control outcomes after these treatments are similar. As a result, complication risks often have a signifi cant role in patients' decision making. To date, compli cation analyses have focused largely on incontinence, impotence and, to a lesser extent, second malignancies after radiotherapy. Although it has been known that some patients require invasive uro logical and anorectal procedures as well as hospital izations after treatment as a result of compli cations, these problems have not been previously well quantified.
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